STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #2654 by analyst upside · 2026-08-12
ARDT
Ardent Health, Inc.
Healthcare · Market Cap $2B · P/E 19.9x
ANALYST PRICE TARGET
+15.6%
implied upside to consensus target
Current Price $10.97
Consensus Target $12.68
Bull Target $14.0
Bear Target $10.0
Analysts Covering 11
ANALYST CONSENSUS - BUY
Strong Buy
1
Buy
6
Hold
4
Sell
0
52-Week Low $7.71
52-Week High $15.48
YTD Return +27.0%
FUNDAMENTALS
Market Cap $2B
P/E Ratio (TTM) 19.9x
Forward P/E 8.9x
EPS (TTM) $0.55
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $6.4B
Profit Margin 1.2%
52-WEEK RANGE
52-Week Low $7.71
52-Week High $15.48
Current Price $10.97
Bear Target $10.0
Bull Target $14.0
● Now $10.97 ● Target $12.68
TRADING DATA
Avg Volume 565K
YTD Return +27.0%
Analyst Count 11
Consensus Buy
Upside to Target +15.6%
Last Updated 2026-08-12

ANALYST SUMMARY

Ardent Health, Inc. (ARDT) is currently trading at $10.97 with a Wall Street consensus price target of $12.68, implying potential upside of 15.6% over the next 12 months. 11 analysts currently cover ARDT, with a consensus rating of Buy - 64% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $14.0, while the most cautious has a target of $10.0.

ARDT operates in the Healthcare sector with a market capitalisation of $2B. The stock is up 27.0% year-to-date and is currently trading near the lower end of its 52-week range of $7.71 – $15.48.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for ARDT, with each firm's 90-day track record across all stocks we track. See full firm rankings →

UBS - Reiterated
Buy → Buy 2026-05-07 33% win rate (6 calls)
RBC Capital - Reiterated
Outperform → Outperform 2026-03-10 Building track record
Leerink Partners - Reiterated
Outperform → Outperform 2026-03-06 29% win rate (7 calls)
JP Morgan - Reiterated
Neutral → Neutral 2026-01-20 43% win rate (7 calls)
UBS - Reiterated
Buy → Buy 2025-12-18 33% win rate (6 calls)
Mizuho - Reiterated
Outperform → Outperform 2025-12-18 Building track record
JP Morgan - Reiterated
Neutral → Neutral 2025-11-24 43% win rate (7 calls)
Mizuho - Reiterated
Outperform → Outperform 2025-11-18 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
56
out of 100
Coverage depth
19/30
Consensus clarity
23/30
Vote unanimity
12/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →